Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH). Inflammation and oxidative stress are known characteristics of NAFLD; however, the precise mec...

Full description

Saved in:
Bibliographic Details
Published inDrug metabolism and disposition Vol. 38; no. 12; pp. 2293 - 2301
Main Authors Hardwick, Rhiannon N., Fisher, Craig D., Canet, Mark J., Lake, April D., Cherrington, Nathan J.
Format Journal Article
LanguageEnglish
Published Bethesda, MD Elsevier Inc 01.12.2010
American Society for Pharmacology and Experimental Therapeutics
The American Society for Pharmacology and Experimental Therapeutics
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH). Inflammation and oxidative stress are known characteristics of NAFLD; however, the precise mechanisms occurring during disease progression remain unclear. The purpose of the current study was to determine whether the expression or function of enzymes involved in the antioxidant response, NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione transferase (GST), and glutamate cysteine ligase, are altered in the progression of human NAFLD. Human livers staged as normal, steatotic, NASH (fatty), and NASH (not fatty) were obtained from the Liver Tissue Cell Distribution System. NQO1 mRNA, protein, and activity tended to increase with disease progression. mRNA levels of the GST isoforms A1, A2, A4, M3, and P1 increased with NAFLD progression. Likewise, GST A and P protein increased with progression; however, GST M protein levels tended to decrease. Of interest, total GST activity toward the substrate 1-chloro-2,4-dinitrobenzene decreased with NAFLD progression. GSH synthesis does not seem to be significantly dysregulated in NAFLD progression; however, the GSH/oxidized glutathione redox ratio seemed to be reduced with disease severity, indicating the presence of oxidative stress and depletion of GSH throughout progression of NAFLD. Malondialdehyde concentrations were significantly increased with disease progression, further indicating the presence of oxidative stress. Nuclear immunohistochemical staining of nuclear factor E2-related factor 2 (Nrf2), an indicator of activation of the transcription factor, was evident in all stages of NAFLD. The current data suggest that Nrf2 activation occurs in response to disease progression followed by induction of specific Nrf2 targets, whereas functionality of specific antioxidant defense enzymes seems to be impaired as NAFLD progresses.
AbstractList Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH). Inflammation and oxidative stress are known characteristics of NAFLD; however, the precise mechanisms occurring during disease progression remain unclear. The purpose of the current study was to determine whether the expression or function of enzymes involved in the antioxidant response, NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione transferase (GST), and glutamate cysteine ligase, are altered in the progression of human NAFLD. Human livers staged as normal, steatotic, NASH (fatty), and NASH (not fatty) were obtained from the Liver Tissue Cell Distribution System. NQO1 mRNA, protein, and activity tended to increase with disease progression. mRNA levels of the GST isoforms A1, A2, A4, M3, and P1 increased with NAFLD progression. Likewise, GST A and P protein increased with progression; however, GST M protein levels tended to decrease. Of interest, total GST activity toward the substrate 1-chloro-2,4-dinitrobenzene decreased with NAFLD progression. GSH synthesis does not seem to be significantly dysregulated in NAFLD progression; however, the GSH/oxidized glutathione redox ratio seemed to be reduced with disease severity, indicating the presence of oxidative stress and depletion of GSH throughout progression of NAFLD. Malondialdehyde concentrations were significantly increased with disease progression, further indicating the presence of oxidative stress. Nuclear immunohistochemical staining of nuclear factor E2-related factor 2 (Nrf2), an indicator of activation of the transcription factor, was evident in all stages of NAFLD. The current data suggest that Nrf2 activation occurs in response to disease progression followed by induction of specific Nrf2 targets, whereas functionality of specific antioxidant defense enzymes seems to be impaired as NAFLD progresses.Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH). Inflammation and oxidative stress are known characteristics of NAFLD; however, the precise mechanisms occurring during disease progression remain unclear. The purpose of the current study was to determine whether the expression or function of enzymes involved in the antioxidant response, NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione transferase (GST), and glutamate cysteine ligase, are altered in the progression of human NAFLD. Human livers staged as normal, steatotic, NASH (fatty), and NASH (not fatty) were obtained from the Liver Tissue Cell Distribution System. NQO1 mRNA, protein, and activity tended to increase with disease progression. mRNA levels of the GST isoforms A1, A2, A4, M3, and P1 increased with NAFLD progression. Likewise, GST A and P protein increased with progression; however, GST M protein levels tended to decrease. Of interest, total GST activity toward the substrate 1-chloro-2,4-dinitrobenzene decreased with NAFLD progression. GSH synthesis does not seem to be significantly dysregulated in NAFLD progression; however, the GSH/oxidized glutathione redox ratio seemed to be reduced with disease severity, indicating the presence of oxidative stress and depletion of GSH throughout progression of NAFLD. Malondialdehyde concentrations were significantly increased with disease progression, further indicating the presence of oxidative stress. Nuclear immunohistochemical staining of nuclear factor E2-related factor 2 (Nrf2), an indicator of activation of the transcription factor, was evident in all stages of NAFLD. The current data suggest that Nrf2 activation occurs in response to disease progression followed by induction of specific Nrf2 targets, whereas functionality of specific antioxidant defense enzymes seems to be impaired as NAFLD progresses.
Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH). Inflammation and oxidative stress are known characteristics of NAFLD; however, the precise mechanisms occurring during disease progression remain unclear. The purpose of the current study was to determine whether the expression or function of enzymes involved in the antioxidant response, NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione transferase (GST), and glutamate cysteine ligase, are altered in the progression of human NAFLD. Human livers staged as normal, steatotic, NASH (fatty), and NASH (not fatty) were obtained from the Liver Tissue Cell Distribution System. NQO1 mRNA, protein, and activity tended to increase with disease progression. mRNA levels of the GST isoforms A1, A2, A4, M3, and P1 increased with NAFLD progression. Likewise, GST A and P protein increased with progression; however, GST M protein levels tended to decrease. Of interest, total GST activity toward the substrate 1-chloro-2,4-dinitrobenzene decreased with NAFLD progression. GSH synthesis does not seem to be significantly dysregulated in NAFLD progression; however, the GSH/oxidized glutathione redox ratio seemed to be reduced with disease severity, indicating the presence of oxidative stress and depletion of GSH throughout progression of NAFLD. Malondialdehyde concentrations were significantly increased with disease progression, further indicating the presence of oxidative stress. Nuclear immunohistochemical staining of nuclear factor E2-related factor 2 (Nrf2), an indicator of activation of the transcription factor, was evident in all stages of NAFLD. The current data suggest that Nrf2 activation occurs in response to disease progression followed by induction of specific Nrf2 targets, whereas functionality of specific antioxidant defense enzymes seems to be impaired as NAFLD progresses.
Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH). Inflammation and oxidative stress are known characteristics of NAFLD; however, the precise mechanisms occurring during disease progression remain unclear. The purpose of the current study was to determine whether the expression or function of enzymes involved in the antioxidant response, NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione transferase (GST), and glutamate cysteine ligase, are altered in the progression of human NAFLD. Human livers staged as normal, steatotic, NASH (fatty), and NASH (not fatty) were obtained from the Liver Tissue Cell Distribution System. NQO1 mRNA, protein, and activity tended to increase with disease progression. mRNA levels of the GST isoforms A1, A2, A4, M3, and P1 increased with NAFLD progression. Likewise, GST A and P protein increased with progression; however, GST M protein levels tended to decrease. Of interest, total GST activity toward the substrate 1-chloro-2,4-dinitrobenzene decreased with NAFLD progression. GSH synthesis does not seem to be significantly dysregulated in NAFLD progression; however, the GSH/oxidized glutathione redox ratio seemed to be reduced with disease severity, indicating the presence of oxidative stress and depletion of GSH throughout progression of NAFLD. Malondialdehyde concentrations were significantly increased with disease progression, further indicating the presence of oxidative stress. Nuclear immunohistochemical staining of nuclear factor E2-related factor 2 (Nrf2), an indicator of activation of the transcription factor, was evident in all stages of NAFLD. The current data suggest that Nrf2 activation occurs in response to disease progression followed by induction of specific Nrf2 targets, whereas functionality of specific antioxidant defense enzymes seems to be impaired as NAFLD progresses.
Author Fisher, Craig D.
Hardwick, Rhiannon N.
Canet, Mark J.
Lake, April D.
Cherrington, Nathan J.
Author_xml – sequence: 1
  givenname: Rhiannon N.
  surname: Hardwick
  fullname: Hardwick, Rhiannon N.
– sequence: 2
  givenname: Craig D.
  surname: Fisher
  fullname: Fisher, Craig D.
– sequence: 3
  givenname: Mark J.
  surname: Canet
  fullname: Canet, Mark J.
– sequence: 4
  givenname: April D.
  surname: Lake
  fullname: Lake, April D.
– sequence: 5
  givenname: Nathan J.
  surname: Cherrington
  fullname: Cherrington, Nathan J.
  email: cherrington@pharmacy.arizona.edu
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23597686$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/20805291$$D View this record in MEDLINE/PubMed
BookMark eNp1UU1rGzEQFSWlcdJeeyx7KT2tK62kXelSCPkG05Z-QG9CK806KruSI8mm7q-vjJ1-QU5vmHnvzTDvBB354AGhlwTPCWnYWzvZUuA5phzj9gmaEd6QGmP57QjNCuBact4eo5OUvmNMGKPyGTpusMC8kWSG3IXbQEwubyvnqzOfXfjhrPa5-gRpFXyC6tL_3E6QdvOPMSwjpFQ01eesl6UbhupmPWlfvQ9ejybchdGZ6krn4rjYeVcXLoFO8Bw9HfSY4MUBT9HXq8sv5zf14sP17fnZojasFbk2PWbUyKYVtEAvZWctl9pIIWWjDbFMU94XNJ3tGR5a0fVci0Z2hDI2WHqK3u19V-t-AmvA56hHtYpu0nGrgnbq34l3d2oZNqqRkjLOisGbg0EM92tIWU0uGRhH7SGskxJYsLbcKgrz1d-rfu94eG8hvD4QdDJ6HKL2xqU_PMpl14q28NieZ2JIKcKgjMu6ZLG70I2KYLVLW5W0S4HVPu0im_8ne3B-VCD2AigBbBxElYwDb8C6CCYrG9xj0l9BScCa
CODEN DMDSAI
CitedBy_id crossref_primary_10_1124_dmd_117_077644
crossref_primary_10_1538_expanim_16_0010
crossref_primary_10_3390_antiox10081222
crossref_primary_10_1124_dmd_114_062703
crossref_primary_10_3109_03602532_2011_558092
crossref_primary_10_1016_j_jhep_2012_11_014
crossref_primary_10_1093_toxsci_kft275
crossref_primary_10_1016_j_fbio_2024_104142
crossref_primary_10_1016_j_lfs_2024_122806
crossref_primary_10_3390_antiox7010012
crossref_primary_10_1016_j_ajpath_2016_03_005
crossref_primary_10_3389_fmed_2021_595371
crossref_primary_10_1186_s12864_023_09160_4
crossref_primary_10_3109_13880209_2015_1060247
crossref_primary_10_1016_j_freeradbiomed_2015_12_014
crossref_primary_10_1038_labinvest_2017_22
crossref_primary_10_1016_j_jhep_2011_05_019
crossref_primary_10_1016_j_mehy_2011_05_034
crossref_primary_10_1124_dmd_116_071415
crossref_primary_10_1016_j_mri_2016_03_009
crossref_primary_10_1186_s12906_017_1762_8
crossref_primary_10_1080_13102818_2019_1674690
crossref_primary_10_3390_antiox9070578
crossref_primary_10_1038_s41598_018_24403_1
crossref_primary_10_1038_srep34719
crossref_primary_10_1007_s00394_015_0877_2
crossref_primary_10_1139_cjpp_2014_0394
crossref_primary_10_1124_dmd_121_000413
crossref_primary_10_3390_antiox13111371
crossref_primary_10_1002_psp4_12185
crossref_primary_10_1371_journal_pone_0143121
crossref_primary_10_1038_nrd_2015_3
crossref_primary_10_1002_hep_26925
crossref_primary_10_1371_journal_pone_0096553
crossref_primary_10_1124_dmd_112_046177
crossref_primary_10_5812_hepatmon_9527
crossref_primary_10_3390_biomedicines8090350
crossref_primary_10_3390_antiox10081289
crossref_primary_10_1111_apt_14952
crossref_primary_10_1124_dmd_113_055996
crossref_primary_10_1007_s11745_015_4084_y
crossref_primary_10_1016_j_freeradbiomed_2013_08_174
crossref_primary_10_1016_j_taap_2024_117185
crossref_primary_10_1111_j_1440_1746_2012_07255_x
crossref_primary_10_3389_fendo_2020_607011
crossref_primary_10_1016_j_bbadis_2018_10_010
crossref_primary_10_3390_antiox9100980
crossref_primary_10_1538_expanim_17_0112
crossref_primary_10_2337_db14_1947
crossref_primary_10_3390_ijms19072034
crossref_primary_10_1111_1440_1681_12040
crossref_primary_10_1038_labinvest_2014_3
crossref_primary_10_1007_s00204_024_03889_x
crossref_primary_10_1179_1351000213Y_0000000050
crossref_primary_10_1016_j_jtcme_2017_05_006
crossref_primary_10_1007_s11095_013_1140_2
crossref_primary_10_1016_j_taap_2019_02_009
crossref_primary_10_4254_wjh_v17_i2_101741
crossref_primary_10_3390_livers3010003
crossref_primary_10_1016_j_taap_2019_114664
crossref_primary_10_1139_cjpp_2016_0681
crossref_primary_10_1111_bcp_12802
crossref_primary_10_3390_ijerph16224334
crossref_primary_10_1089_jmf_2021_K_0090
crossref_primary_10_1080_13510002_2018_1546985
crossref_primary_10_1038_s41598_020_65481_4
crossref_primary_10_1002_hep_30368
crossref_primary_10_1177_0960327113506723
crossref_primary_10_1016_j_fct_2017_02_039
crossref_primary_10_1124_dmd_111_040592
crossref_primary_10_5937_mp70_17890
crossref_primary_10_3390_antiox11030447
crossref_primary_10_4161_cc_20259
crossref_primary_10_1093_toxsci_kft230
crossref_primary_10_1002_jcph_768
crossref_primary_10_1007_s13318_020_00666_w
crossref_primary_10_1016_j_cyto_2018_10_010
crossref_primary_10_3389_fimmu_2022_870239
crossref_primary_10_1016_j_csbj_2018_10_013
crossref_primary_10_1124_dmd_111_041095
crossref_primary_10_3390_receptors2010001
crossref_primary_10_1016_j_cbi_2018_04_010
crossref_primary_10_1186_s13023_017_0689_y
crossref_primary_10_3390_nu13103334
crossref_primary_10_4254_wjh_v7_i27_2749
crossref_primary_10_1007_s12072_020_10112_3
crossref_primary_10_1124_dmd_111_041012
crossref_primary_10_1016_j_pharmthera_2015_03_005
crossref_primary_10_1007_s11095_022_03295_x
crossref_primary_10_1016_j_taap_2013_01_022
crossref_primary_10_1124_jpet_114_220764
crossref_primary_10_1016_j_metabol_2017_04_011
crossref_primary_10_1093_toxsci_kfu156
crossref_primary_10_1517_17425255_2014_936378
crossref_primary_10_1089_ars_2013_5486
crossref_primary_10_1089_ars_2016_6776
crossref_primary_10_3109_10715762_2013_837577
crossref_primary_10_1111_hepr_12992
crossref_primary_10_1016_j_cca_2011_04_013
crossref_primary_10_1124_dmd_112_048439
crossref_primary_10_1139_cjpp_2019_0383
crossref_primary_10_1124_jpet_116_238790
crossref_primary_10_1016_j_jbior_2018_11_004
crossref_primary_10_3389_fendo_2023_1050049
crossref_primary_10_1016_j_jhep_2014_02_021
crossref_primary_10_1155_2015_597134
crossref_primary_10_1093_toxsci_kfx253
crossref_primary_10_3892_etm_2013_1434
crossref_primary_10_1586_17446651_2014_938053
crossref_primary_10_1016_j_freeradbiomed_2021_03_015
crossref_primary_10_1021_acs_chemrestox_0c00131
crossref_primary_10_1016_j_metabol_2013_06_012
crossref_primary_10_1111_liv_13362
crossref_primary_10_1128_MCB_00170_16
crossref_primary_10_3945_ajcn_115_118570
crossref_primary_10_1016_j_foodchem_2025_143956
crossref_primary_10_1124_dmd_113_050930
crossref_primary_10_3945_jn_111_148544
crossref_primary_10_1097_MCO_0b013e328357f747
crossref_primary_10_1080_03602532_2017_1293683
crossref_primary_10_1152_ajpendo_00345_2017
crossref_primary_10_1016_j_freeradbiomed_2022_06_226
crossref_primary_10_1124_dmd_112_049676
crossref_primary_10_1016_S1499_3872_15_60425_8
crossref_primary_10_1089_met_2017_0131
crossref_primary_10_1016_j_bcmd_2011_03_004
crossref_primary_10_1590_0004_2730000002831
crossref_primary_10_1002_jbt_22035
crossref_primary_10_3109_03602532_2011_577781
crossref_primary_10_3168_jds_2012_5900
crossref_primary_10_1089_dna_2011_1343
crossref_primary_10_1124_jpet_118_255018
crossref_primary_10_1155_2023_2877350
crossref_primary_10_1016_j_lfs_2022_120956
crossref_primary_10_3109_10408444_2014_931341
crossref_primary_10_1016_j_jnutbio_2025_109842
crossref_primary_10_1177_0884533612471766
crossref_primary_10_1016_j_etap_2023_104138
crossref_primary_10_1292_jvms_20_0479
crossref_primary_10_1371_journal_pone_0127991
crossref_primary_10_1007_s13273_019_00066_5
crossref_primary_10_1016_j_jff_2016_08_050
Cites_doi 10.1002/jbt.20177
10.1007/s00204-008-0312-z
10.1016/j.freeradbiomed.2004.02.074
10.2133/dmpk.21.437
10.1056/NEJMra011775
10.1016/S0891-5849(00)00306-3
10.1016/j.mrgentox.2008.09.009
10.1016/j.annepidem.2007.05.013
10.1074/mcp.M800070-MCP200
10.2217/14622416.10.1.29
10.1016/S0009-8981(03)00200-6
10.1016/j.canlet.2004.01.003
10.1080/03602530600971974
10.18388/abp.2006_3384
10.1124/dmd.109.027466
10.3748/wjg.v12.i12.1937
10.1006/bbrc.1997.6943
10.1146/annurev.pharmtox.45.120403.095857
10.1681/ASN.2008020227
10.1016/S0076-6879(05)01007-4
10.1074/jbc.M000361200
10.1002/hep.20701
10.1016/S0076-6879(04)82008-1
10.1016/j.molmed.2007.12.003
10.1016/j.tox.2006.11.052
10.1080/07853890802552437
10.1016/S0076-6879(05)01002-5
10.2131/jts.32.453
10.1016/S0009-2797(97)00174-9
10.1080/01926230701311344
10.1016/S0009-2797(97)00096-3
10.1016/S0076-6879(04)82019-6
10.1379/CSC-217.1
10.1016/j.mam.2008.05.005
10.1016/j.bbrc.2007.03.174
ContentType Journal Article
Copyright 2010 American Society for Pharmacology and Experimental Therapeutics
2015 INIST-CNRS
Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics
Copyright_xml – notice: 2010 American Society for Pharmacology and Experimental Therapeutics
– notice: 2015 INIST-CNRS
– notice: Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1124/dmd.110.035006
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1521-009X
EndPage 2301
ExternalDocumentID PMC2993454
20805291
23597686
10_1124_dmd_110_035006
S0090955624025753
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NLM NIH HHS
  grantid: HHSN267200700004G
– fundername: NIEHS NIH HHS
  grantid: T32 ES007091
– fundername: NIDDK NIH HHS
  grantid: DK068039
– fundername: NIDDK NIH HHS
  grantid: N01-DK-7-0004
– fundername: NLM NIH HHS
  grantid: HHSN267200700004C
– fundername: NIEHS NIH HHS
  grantid: P30 ES006694
– fundername: NCCIH NIH HHS
  grantid: F31 AT002842
– fundername: NIEHS NIH HHS
  grantid: ES006694
– fundername: NIDDK NIH HHS
  grantid: R01 DK068039
– fundername: NCCIH NIH HHS
  grantid: AT002842
– fundername: National Institutes of Health
  grantid: DK068039; ES006694; AT002842; N01-DK-7-0004/HHSN267200700004C
GroupedDBID ---
.GJ
0R~
18M
2WC
4.4
53G
5GY
5RE
5VS
AAXUO
ABJNI
ABSQV
ACGFO
ACGFS
ACIWK
ACPRK
ADBBV
AENEX
AERNN
AFFNX
AFOSN
AFRAH
AI.
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
F9R
FDB
GX1
H13
HZ~
IH2
INIJC
KQ8
LSO
M41
O9-
OK1
P2P
R0Z
RHI
ROL
RPT
SJN
TR2
VH1
W8F
WH7
WOQ
YCJ
YHG
ZGI
ZXP
~KM
AALRI
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c468t-cb043c926833c9b997dd59ac98992ac1d4a35bc1dc7db40f687b5a82971344fd3
ISSN 0090-9556
1521-009X
IngestDate Thu Aug 21 18:30:46 EDT 2025
Fri Jul 11 04:07:41 EDT 2025
Mon Jul 21 06:01:14 EDT 2025
Mon Jul 21 09:15:36 EDT 2025
Tue Jul 01 05:28:27 EDT 2025
Thu Apr 24 22:51:08 EDT 2025
Sun Apr 06 06:53:03 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords NQO1
GSSG
NAFLD
DAB
DCPIP
GST
CDNB
TBARS
MDA
NASH
GCL
GCLC
ARE
Nrf2
ROS
GCLM
HNE
ERK
Human
Clinical stage
Enzyme
Non alcoholic steatohepatitis
Digestive diseases
Hepatic disease
Antioxidant
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c468t-cb043c926833c9b997dd59ac98992ac1d4a35bc1dc7db40f687b5a82971344fd3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://dmd.aspetjournals.org/content/dmd/38/12/2293.full.pdf
PMID 20805291
PQID 808464688
PQPubID 23479
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2993454
proquest_miscellaneous_808464688
pubmed_primary_20805291
pascalfrancis_primary_23597686
crossref_citationtrail_10_1124_dmd_110_035006
crossref_primary_10_1124_dmd_110_035006
elsevier_sciencedirect_doi_10_1124_dmd_110_035006
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-12-01
PublicationDateYYYYMMDD 2010-12-01
PublicationDate_xml – month: 12
  year: 2010
  text: 2010-12-01
  day: 01
PublicationDecade 2010
PublicationPlace Bethesda, MD
PublicationPlace_xml – name: Bethesda, MD
– name: Netherlands
PublicationTitle Drug metabolism and disposition
PublicationTitleAlternate Drug Metab Dispos
PublicationYear 2010
Publisher Elsevier Inc
American Society for Pharmacology and Experimental Therapeutics
The American Society for Pharmacology and Experimental Therapeutics
Publisher_xml – name: Elsevier Inc
– name: American Society for Pharmacology and Experimental Therapeutics
– name: The American Society for Pharmacology and Experimental Therapeutics
References Aleksunes, Slitt, Maher, Dieter, Knight, Goedken, Cherrington, Chan, Klaassen, Manautou (bib4) 2006; 11
Moffit, Aleksunes, Kardas, Slitt, Klaassen, Manautou (bib28) 2007; 230
Kleiner, Brunt, Van Natta, Behling, Contos, Cummings, Ferrell, Liu, Torbenson, Unalp-Arida (bib19) 2005; 41
Martin, Collier, Bowen, Pritsos, Goodrich, Arger, Cutter, Pritsos (bib26) 2009; 674
McCullough (bib27) 2006; 40
Fisher, Jackson, Lickteig, Augustine, Cherrington (bib11) 2008; 82
Adams, Lindor (bib1) 2007; 17
Coles, Kadlubar (bib9) 2005; 401
Henderson, Wolf (bib14) 2005; 401
Lu (bib22) 2009; 30
Sakai, Muramatsu (bib34) 2007; 357
Pastore, Federici, Bertini, Piemonte (bib32) 2003; 333
Clapper, Szarka (bib7) 1998; 111–112
Zhang (bib37) 2006; 38
Marra, Gastaldelli, Svegliati Baroni, Tell, Tiribelli (bib25) 2008; 14
Jaiswal (bib17) 2000; 29
Talalay, Dinkova-Kostova (bib35) 2004; 382
Czeczot, Scibior, Skrzycki, Podsiad (bib10) 2006; 53
Lin, Hung, Wei, Tarng (bib21) 2009; 20
Angulo (bib6) 2002; 346
Nguyen, Huang, Pickett (bib31) 2000; 275
Higashi, Hiai, Higashi, Muramatsu (bib15) 2004; 209
Jaiswal (bib18) 2004; 36
Manfredi, Calvi, del Fiandra, Botto, Biagini, Andreassi (bib23) 2009; 10
van Iersel, Ploemen, Lo Bello, Federici, van Bladeren (bib36) 1997; 108
Nagata, Suzuki, Sakaguchi (bib29) 2007; 32
Ross, Siegel (bib33) 2004; 382
Aleksunes, Manautou (bib3) 2007; 35
Hayes, Flanagan, Jowsey (bib13) 2005; 45
Lickteig, Fisher, Augustine, Cherrington (bib20) 2007; 21
Mannervik, Jemth (bib24) 1999
Nakata, Tanaka, Nakano, Adachi, Tanaka, Kaminuma, Ishikawa (bib30) 2006; 21
Aleksunes, Goedken, Manautou (bib2) 2006; 12
Ali, Cusi (bib5) 2009; 41
Itoh, Chiba, Takahashi, Ishii, Igarashi, Katoh, Oyake, Hayashi, Satoh, Hatayama (bib16) 1997; 236
Fisher, Lickteig, Augustine, Ranger-Moore, Jackson, Ferguson, Cherrington (bib12) 2009; 37
Codreanu, Zhang, Sobecki, Billheimer, Liebler (bib8) 2009; 8
McCullough (10.1124/dmd.110.035006_bib27) 2006; 40
Talalay (10.1124/dmd.110.035006_bib35) 2004; 382
Aleksunes (10.1124/dmd.110.035006_bib2) 2006; 12
Itoh (10.1124/dmd.110.035006_bib16) 1997; 236
Sakai (10.1124/dmd.110.035006_bib34) 2007; 357
Fisher (10.1124/dmd.110.035006_bib12) 2009; 37
Fisher (10.1124/dmd.110.035006_bib11) 2008; 82
Ross (10.1124/dmd.110.035006_bib33) 2004; 382
Angulo (10.1124/dmd.110.035006_bib6) 2002; 346
Czeczot (10.1124/dmd.110.035006_bib10) 2006; 53
Nakata (10.1124/dmd.110.035006_bib30) 2006; 21
Codreanu (10.1124/dmd.110.035006_bib8) 2009; 8
Kleiner (10.1124/dmd.110.035006_bib19) 2005; 41
Lickteig (10.1124/dmd.110.035006_bib20) 2007; 21
Marra (10.1124/dmd.110.035006_bib25) 2008; 14
Moffit (10.1124/dmd.110.035006_bib28) 2007; 230
Jaiswal (10.1124/dmd.110.035006_bib17) 2000; 29
Henderson (10.1124/dmd.110.035006_bib14) 2005; 401
Aleksunes (10.1124/dmd.110.035006_bib3) 2007; 35
Coles (10.1124/dmd.110.035006_bib9) 2005; 401
Lin (10.1124/dmd.110.035006_bib21) 2009; 20
Jaiswal (10.1124/dmd.110.035006_bib18) 2004; 36
Nagata (10.1124/dmd.110.035006_bib29) 2007; 32
Ali (10.1124/dmd.110.035006_bib5) 2009; 41
Lu (10.1124/dmd.110.035006_bib22) 2009; 30
van Iersel (10.1124/dmd.110.035006_bib36) 1997; 108
Nguyen (10.1124/dmd.110.035006_bib31) 2000; 275
Higashi (10.1124/dmd.110.035006_bib15) 2004; 209
Aleksunes (10.1124/dmd.110.035006_bib4) 2006; 11
Mannervik (10.1124/dmd.110.035006_bib24) 1999
Manfredi (10.1124/dmd.110.035006_bib23) 2009; 10
Hayes (10.1124/dmd.110.035006_bib13) 2005; 45
Clapper (10.1124/dmd.110.035006_bib7) 1998; 111–112
Pastore (10.1124/dmd.110.035006_bib32) 2003; 333
Martin (10.1124/dmd.110.035006_bib26) 2009; 674
Zhang (10.1124/dmd.110.035006_bib37) 2006; 38
Adams (10.1124/dmd.110.035006_bib1) 2007; 17
References_xml – volume: 382
  start-page: 115
  year: 2004
  end-page: 144
  ident: bib33
  article-title: NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics
  publication-title: Methods Enzymol
– volume: 346
  start-page: 1221
  year: 2002
  end-page: 1231
  ident: bib6
  article-title: Nonalcoholic fatty liver disease
  publication-title: N Engl J Med
– volume: 38
  start-page: 769
  year: 2006
  end-page: 789
  ident: bib37
  article-title: Mechanistic studies of the Nrf2-Keap1 signaling pathway
  publication-title: Drug Metab Rev
– volume: 108
  start-page: 67
  year: 1997
  end-page: 78
  ident: bib36
  article-title: Interactions of α,β-unsaturated aldehydes and ketones with human glutathione
  publication-title: Chem Biol Interact
– volume: 209
  start-page: 155
  year: 2004
  end-page: 163
  ident: bib15
  article-title: Regulatory mechanism of glutathione S-transferase P-form during chemical hepatocarcinogenesis: old wine in a new bottle
  publication-title: Cancer Lett
– volume: 21
  start-page: 437
  year: 2006
  end-page: 457
  ident: bib30
  article-title: Nuclear receptor-mediated transcriptional regulation in phase I, II, and III xenobiotic metabolizing systems
  publication-title: Drug Metab Pharmacokinet
– volume: 230
  start-page: 197
  year: 2007
  end-page: 206
  ident: bib28
  article-title: Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen
  publication-title: Toxicology
– volume: 35
  start-page: 459
  year: 2007
  end-page: 473
  ident: bib3
  article-title: Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease
  publication-title: Toxicol Pathol
– volume: 20
  start-page: 405
  year: 2009
  end-page: 415
  ident: bib21
  article-title: GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients
  publication-title: J Am Soc Nephrol
– year: 1999
  ident: bib24
  article-title: Measurement of glutathione transferases
  publication-title: Current Protocols in Toxicology
– volume: 41
  start-page: 265
  year: 2009
  end-page: 278
  ident: bib5
  article-title: New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
  publication-title: Ann Med
– volume: 82
  start-page: 959
  year: 2008
  end-page: 964
  ident: bib11
  article-title: Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis
  publication-title: Arch Toxicol
– volume: 382
  start-page: 355
  year: 2004
  end-page: 364
  ident: bib35
  article-title: Role of nicotinamide quinone oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates
  publication-title: Methods Enzymol
– volume: 40
  start-page: S17
  year: 2006
  end-page: S29
  ident: bib27
  article-title: Pathophysiology of nonalcoholic steatohepatitis
  publication-title: J Clin Gastroenterol
– volume: 10
  start-page: 29
  year: 2009
  end-page: 34
  ident: bib23
  article-title: Glutathione S-transferase T1- and M1-null genotypes and coronary artery disease risk in patients with type 2 diabetes mellitus
  publication-title: Pharmacogenomics
– volume: 36
  start-page: 1199
  year: 2004
  end-page: 1207
  ident: bib18
  article-title: Nrf2 signaling in coordinated activation of antioxidant gene expression
  publication-title: Free Radic Biol Med
– volume: 14
  start-page: 72
  year: 2008
  end-page: 81
  ident: bib25
  article-title: Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis
  publication-title: Trends Mol Med
– volume: 357
  start-page: 575
  year: 2007
  end-page: 578
  ident: bib34
  article-title: Regulation of glutathione transferase P: a tumor marker of hepatocarcinogenesis
  publication-title: Biochem Biophys Res Commun
– volume: 236
  start-page: 313
  year: 1997
  end-page: 322
  ident: bib16
  article-title: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements
  publication-title: Biochem Biophys Res Commun
– volume: 275
  start-page: 15466
  year: 2000
  end-page: 15473
  ident: bib31
  article-title: Transcriptional regulation of the antioxidant response element. Activation by Nrf2 and repression by MafK
  publication-title: J Biol Chem
– volume: 32
  start-page: 453
  year: 2007
  end-page: 468
  ident: bib29
  article-title: Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis
  publication-title: J Toxicol Sci
– volume: 401
  start-page: 9
  year: 2005
  end-page: 42
  ident: bib9
  article-title: Human alpha class glutathione
  publication-title: Methods Enzymol
– volume: 29
  start-page: 254
  year: 2000
  end-page: 262
  ident: bib17
  article-title: Regulation of genes encoding NAD(P)H:quinone oxidoreductases
  publication-title: Free Radic Biol Med
– volume: 45
  start-page: 51
  year: 2005
  end-page: 88
  ident: bib13
  article-title: Glutathione transferases
  publication-title: Annu Rev Pharmacol Toxicol
– volume: 30
  start-page: 42
  year: 2009
  end-page: 59
  ident: bib22
  article-title: Regulation of glutathione synthesis
  publication-title: Mol Aspects Med
– volume: 401
  start-page: 116
  year: 2005
  end-page: 135
  ident: bib14
  article-title: Disruption of the glutathione transferase pi class genes
  publication-title: Methods Enzymol
– volume: 12
  start-page: 1937
  year: 2006
  end-page: 1940
  ident: bib2
  article-title: Up-regulation of NAD(P)H quinone oxidoreductase 1 during human liver injury
  publication-title: World J Gastroenterol
– volume: 53
  start-page: 237
  year: 2006
  end-page: 242
  ident: bib10
  article-title: Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma
  publication-title: Acta Biochim Pol
– volume: 333
  start-page: 19
  year: 2003
  end-page: 39
  ident: bib32
  article-title: Analysis of glutathione: implication in redox and detoxification
  publication-title: Clin Chim Acta
– volume: 37
  start-page: 2087
  year: 2009
  end-page: 2094
  ident: bib12
  article-title: Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease
  publication-title: Drug Metab Dispos
– volume: 111–112
  start-page: 377
  year: 1998
  end-page: 388
  ident: bib7
  article-title: Glutathione
  publication-title: Chem Biol Interact
– volume: 17
  start-page: 863
  year: 2007
  end-page: 869
  ident: bib1
  article-title: Nonalcoholic fatty liver disease
  publication-title: Ann Epidemiol
– volume: 674
  start-page: 93
  year: 2009
  end-page: 100
  ident: bib26
  article-title: Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress
  publication-title: Mutat Res
– volume: 41
  start-page: 1313
  year: 2005
  end-page: 1321
  ident: bib19
  article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease
  publication-title: Hepatology
– volume: 11
  start-page: 356
  year: 2006
  end-page: 363
  ident: bib4
  article-title: Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis
  publication-title: Cell Stress Chaperones
– volume: 21
  start-page: 216
  year: 2007
  end-page: 220
  ident: bib20
  article-title: Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis
  publication-title: J Biochem Mol Toxicol
– volume: 8
  start-page: 670
  year: 2009
  end-page: 680
  ident: bib8
  article-title: Global analysis of protein damage by the lipid electrophile 4-hydroxy-2-nonenal
  publication-title: Mol Cell Proteomics
– volume: 21
  start-page: 216
  year: 2007
  ident: 10.1124/dmd.110.035006_bib20
  article-title: Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis
  publication-title: J Biochem Mol Toxicol
  doi: 10.1002/jbt.20177
– volume: 82
  start-page: 959
  year: 2008
  ident: 10.1124/dmd.110.035006_bib11
  article-title: Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis
  publication-title: Arch Toxicol
  doi: 10.1007/s00204-008-0312-z
– volume: 36
  start-page: 1199
  year: 2004
  ident: 10.1124/dmd.110.035006_bib18
  article-title: Nrf2 signaling in coordinated activation of antioxidant gene expression
  publication-title: Free Radic Biol Med
  doi: 10.1016/j.freeradbiomed.2004.02.074
– volume: 21
  start-page: 437
  year: 2006
  ident: 10.1124/dmd.110.035006_bib30
  article-title: Nuclear receptor-mediated transcriptional regulation in phase I, II, and III xenobiotic metabolizing systems
  publication-title: Drug Metab Pharmacokinet
  doi: 10.2133/dmpk.21.437
– volume: 346
  start-page: 1221
  year: 2002
  ident: 10.1124/dmd.110.035006_bib6
  article-title: Nonalcoholic fatty liver disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra011775
– volume: 40
  start-page: S17
  year: 2006
  ident: 10.1124/dmd.110.035006_bib27
  article-title: Pathophysiology of nonalcoholic steatohepatitis
  publication-title: J Clin Gastroenterol
– volume: 29
  start-page: 254
  year: 2000
  ident: 10.1124/dmd.110.035006_bib17
  article-title: Regulation of genes encoding NAD(P)H:quinone oxidoreductases
  publication-title: Free Radic Biol Med
  doi: 10.1016/S0891-5849(00)00306-3
– volume: 674
  start-page: 93
  year: 2009
  ident: 10.1124/dmd.110.035006_bib26
  article-title: Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress
  publication-title: Mutat Res
  doi: 10.1016/j.mrgentox.2008.09.009
– volume: 17
  start-page: 863
  year: 2007
  ident: 10.1124/dmd.110.035006_bib1
  article-title: Nonalcoholic fatty liver disease
  publication-title: Ann Epidemiol
  doi: 10.1016/j.annepidem.2007.05.013
– volume: 8
  start-page: 670
  year: 2009
  ident: 10.1124/dmd.110.035006_bib8
  article-title: Global analysis of protein damage by the lipid electrophile 4-hydroxy-2-nonenal
  publication-title: Mol Cell Proteomics
  doi: 10.1074/mcp.M800070-MCP200
– volume: 10
  start-page: 29
  year: 2009
  ident: 10.1124/dmd.110.035006_bib23
  article-title: Glutathione S-transferase T1- and M1-null genotypes and coronary artery disease risk in patients with type 2 diabetes mellitus
  publication-title: Pharmacogenomics
  doi: 10.2217/14622416.10.1.29
– volume: 333
  start-page: 19
  year: 2003
  ident: 10.1124/dmd.110.035006_bib32
  article-title: Analysis of glutathione: implication in redox and detoxification
  publication-title: Clin Chim Acta
  doi: 10.1016/S0009-8981(03)00200-6
– volume: 209
  start-page: 155
  year: 2004
  ident: 10.1124/dmd.110.035006_bib15
  article-title: Regulatory mechanism of glutathione S-transferase P-form during chemical hepatocarcinogenesis: old wine in a new bottle
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2004.01.003
– volume: 38
  start-page: 769
  year: 2006
  ident: 10.1124/dmd.110.035006_bib37
  article-title: Mechanistic studies of the Nrf2-Keap1 signaling pathway
  publication-title: Drug Metab Rev
  doi: 10.1080/03602530600971974
– volume: 53
  start-page: 237
  year: 2006
  ident: 10.1124/dmd.110.035006_bib10
  article-title: Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma
  publication-title: Acta Biochim Pol
  doi: 10.18388/abp.2006_3384
– volume: 37
  start-page: 2087
  year: 2009
  ident: 10.1124/dmd.110.035006_bib12
  article-title: Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.109.027466
– volume: 12
  start-page: 1937
  year: 2006
  ident: 10.1124/dmd.110.035006_bib2
  article-title: Up-regulation of NAD(P)H quinone oxidoreductase 1 during human liver injury
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v12.i12.1937
– volume: 236
  start-page: 313
  year: 1997
  ident: 10.1124/dmd.110.035006_bib16
  article-title: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements
  publication-title: Biochem Biophys Res Commun
  doi: 10.1006/bbrc.1997.6943
– volume: 45
  start-page: 51
  year: 2005
  ident: 10.1124/dmd.110.035006_bib13
  article-title: Glutathione transferases
  publication-title: Annu Rev Pharmacol Toxicol
  doi: 10.1146/annurev.pharmtox.45.120403.095857
– volume: 20
  start-page: 405
  year: 2009
  ident: 10.1124/dmd.110.035006_bib21
  article-title: GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2008020227
– volume: 401
  start-page: 116
  year: 2005
  ident: 10.1124/dmd.110.035006_bib14
  article-title: Disruption of the glutathione transferase pi class genes
  publication-title: Methods Enzymol
  doi: 10.1016/S0076-6879(05)01007-4
– volume: 275
  start-page: 15466
  year: 2000
  ident: 10.1124/dmd.110.035006_bib31
  article-title: Transcriptional regulation of the antioxidant response element. Activation by Nrf2 and repression by MafK
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M000361200
– volume: 41
  start-page: 1313
  year: 2005
  ident: 10.1124/dmd.110.035006_bib19
  article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease
  publication-title: Hepatology
  doi: 10.1002/hep.20701
– volume: 382
  start-page: 115
  year: 2004
  ident: 10.1124/dmd.110.035006_bib33
  article-title: NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics
  publication-title: Methods Enzymol
  doi: 10.1016/S0076-6879(04)82008-1
– volume: 14
  start-page: 72
  year: 2008
  ident: 10.1124/dmd.110.035006_bib25
  article-title: Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2007.12.003
– volume: 230
  start-page: 197
  year: 2007
  ident: 10.1124/dmd.110.035006_bib28
  article-title: Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen
  publication-title: Toxicology
  doi: 10.1016/j.tox.2006.11.052
– volume: 41
  start-page: 265
  year: 2009
  ident: 10.1124/dmd.110.035006_bib5
  article-title: New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
  publication-title: Ann Med
  doi: 10.1080/07853890802552437
– volume: 401
  start-page: 9
  year: 2005
  ident: 10.1124/dmd.110.035006_bib9
  article-title: Human alpha class glutathione S-transferases: genetic polymorphism, expression, and susceptibility to disease
  publication-title: Methods Enzymol
  doi: 10.1016/S0076-6879(05)01002-5
– year: 1999
  ident: 10.1124/dmd.110.035006_bib24
  article-title: Measurement of glutathione transferases
– volume: 32
  start-page: 453
  year: 2007
  ident: 10.1124/dmd.110.035006_bib29
  article-title: Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis
  publication-title: J Toxicol Sci
  doi: 10.2131/jts.32.453
– volume: 111–112
  start-page: 377
  year: 1998
  ident: 10.1124/dmd.110.035006_bib7
  article-title: Glutathione S-transferases—biomarkers of cancer risk and chemopreventive response
  publication-title: Chem Biol Interact
  doi: 10.1016/S0009-2797(97)00174-9
– volume: 35
  start-page: 459
  year: 2007
  ident: 10.1124/dmd.110.035006_bib3
  article-title: Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease
  publication-title: Toxicol Pathol
  doi: 10.1080/01926230701311344
– volume: 108
  start-page: 67
  year: 1997
  ident: 10.1124/dmd.110.035006_bib36
  article-title: Interactions of α,β-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1
  publication-title: Chem Biol Interact
  doi: 10.1016/S0009-2797(97)00096-3
– volume: 382
  start-page: 355
  year: 2004
  ident: 10.1124/dmd.110.035006_bib35
  article-title: Role of nicotinamide quinone oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates
  publication-title: Methods Enzymol
  doi: 10.1016/S0076-6879(04)82019-6
– volume: 11
  start-page: 356
  year: 2006
  ident: 10.1124/dmd.110.035006_bib4
  article-title: Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis
  publication-title: Cell Stress Chaperones
  doi: 10.1379/CSC-217.1
– volume: 30
  start-page: 42
  year: 2009
  ident: 10.1124/dmd.110.035006_bib22
  article-title: Regulation of glutathione synthesis
  publication-title: Mol Aspects Med
  doi: 10.1016/j.mam.2008.05.005
– volume: 357
  start-page: 575
  year: 2007
  ident: 10.1124/dmd.110.035006_bib34
  article-title: Regulation of glutathione transferase P: a tumor marker of hepatocarcinogenesis
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2007.03.174
SSID ssj0014439
Score 2.4006848
Snippet Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from...
Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2293
SubjectTerms Adult
Antioxidants - metabolism
Biological and medical sciences
Disease Progression
Fatty Liver - enzymology
Fatty Liver - pathology
Gastroenterology. Liver. Pancreas. Abdomen
Glutamate-Cysteine Ligase - analysis
Glutamate-Cysteine Ligase - genetics
Glutathione - metabolism
Glutathione Transferase - analysis
Glutathione Transferase - genetics
Humans
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Medical sciences
NAD(P)H Dehydrogenase (Quinone) - analysis
NAD(P)H Dehydrogenase (Quinone) - genetics
NF-E2-Related Factor 2 - metabolism
Other diseases. Semiology
Pharmacology. Drug treatments
Title Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease
URI https://dx.doi.org/10.1124/dmd.110.035006
https://www.ncbi.nlm.nih.gov/pubmed/20805291
https://www.proquest.com/docview/808464688
https://pubmed.ncbi.nlm.nih.gov/PMC2993454
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb5swFLay7mXSNO3e7FL5YeoeUjIwJsBjlaSqujbqplTKG8I2pEgJjdJEWvur9xN2jI1xukTa-gIRGKxwvs8-xz4XhL6kPGeCep6Thzx0aEZih-WuAF4JCrOlAC1V7uhejHqnV_RsEkxard-W19J6xbr8fmtcyWOkCtdArjJK9j8ka14KF-A3yBeOIGE4_pOMB8apQq5aSL_FX4WATyUX5aXna9YZlvd388rnSoYEVLa1dBUCFXOqss2qRfyR1MerWrkF75ykK3jjuXy3TM5p9m-0CjtYrqey8DSgZ1ZX2BCF8f5qhrSlqMu0_7wGEJaAs1HX4MWUXO8v02LaGZg7_bTMTBhR58xcP0-VH9HxYlnM6vZ6veIv349xEzBTbnimXjapulXmqaFd4mDcRKPZi5hu7DpxEOhk2noIJ54DNyb2GO9HNpaJPWITVaFRz_5gkXnbZxZCAQ5iLmTgRFfux1aZElYWzBbzCmfElWUiVA2yB7m8Ly_6MP37NKBP0FMCho0cmb__aPa9KPWVwab_l04zCp1_2-xaJrHW_ezSqJ4v0lvgea4KtGyzoB46Alua1fgleqFNInys8P0KtbLyNTrUgro7wrZQjvAhtkX4BhWGBLgosUUCXJMAaxLI-xYJsCIBvslxRQJskwBXJMAVCbAmwVt0dTIc908dXT_E4bQXrRzOXOrzmPQiH04sjkMhgjjlcRTHJOUwGqV-wODMQ8Gom_eikAWpjDX3fEpz4b9De8CNbB9hElLG8rDn5aGgPhVxlHs88yMB5jsDNbiNnFoGCdfJ9WWNl1lSGdmEJiA--OEmSnxt9NW0X6i0MjtberVIE60UK2U3AWTufOZgQ_amC-IHYH5E0ADXYEhgOpF7hMDtm_VtErlgkMDXi9rovcJG87DGWxuFG6gxDWSm-s07ZXFdZazXoP_w6Cc_omfNWPIJ7a2W6-wzWAMrdlAR6A-qZxDi
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diversity+in+Antioxidant+Response+Enzymes+in+Progressive+Stages+of+Human+Nonalcoholic+Fatty+Liver+Disease&rft.jtitle=Drug+metabolism+and+disposition&rft.au=Hardwick%2C+Rhiannon+N.&rft.au=Fisher%2C+Craig+D.&rft.au=Canet%2C+Mark+J.&rft.au=Lake%2C+April+D.&rft.date=2010-12-01&rft.pub=The+American+Society+for+Pharmacology+and+Experimental+Therapeutics&rft.issn=0090-9556&rft.eissn=1521-009X&rft.volume=38&rft.issue=12&rft.spage=2293&rft.epage=2301&rft_id=info:doi/10.1124%2Fdmd.110.035006&rft_id=info%3Apmid%2F20805291&rft.externalDocID=PMC2993454
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-9556&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-9556&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-9556&client=summon